1. EGFR tests included for NSCLC in WHO’s third Essential Diagnostics List

2. Germany has a liquid biopsy tariff for locally advanced or metastatic NSCLC

3. Breast cancer recurrence risk scores: Oncotype DX first to be nationally reimbursed in Germany but others may soon join the game